Screening for more potent LMP inducing compounds and designing a more selective delivery system to cancer cells through targeted nanoparticles may offer opportunities to develop novel effective therapeutic approaches for platinum-refractory lung cancer. This evidence concerns the gene PDLIM7 and lung carcinoma.